The Chocolate Touch Study



Status:Recruiting
Conditions:Peripheral Vascular Disease, Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - Any
Updated:9/13/2018
Start Date:July 26, 2017
End Date:December 2026
Contact:Kristine Orosz, BS
Email:korosz@trirememedical.com
Phone:925-931-1300

Use our guide to learn which trials are right for you!

A Randomized Trial to Confirm the Safety and Effectiveness of Chocolate Touch™ Paclitaxel Coated Balloon Catheter, in Above the Knee Lesions

The Chocolate Touch study is a randomized, multi-center, prospective, adaptive study,
designed to show sufficient safety and effectiveness of the Chocolate Touch™ for use in
superficial femoral or popliteal arteries with the intention of obtaining regulatory approval
to market this device in the United States

The primary objective of the Chocolate Touch study is to demonstrate non-inferior safety and
non-inferior effectiveness of the Chocolate Touch™ compared to the Lutonix® drug coated
balloon catheter. These data are intended to show safety and effectiveness of the Chocolate
Touch sufficient to support regulatory approval to market this device in the United States
for use in superficial femoral or popliteal arteries.

Study success is defined as statistical demonstration of the non-inferiority hypothesis tests
for both the primary safety and effectiveness hypothesis.

Inclusion Criteria:

1. Minimum of 18 years of age

2. Intermittent claudication or ischemic rest pain (Rutherford 2-4)

3. Life Expectancy >2 years

4. Patient has agreed to follow-up requirements and given informed consent

5. Lesion successfully crossed with a guidewire

6. Lesion in the superficial femoral or popliteal artery

7. Target lesion >70% stenosis

8. Reference Vessel Diameter between 3.5 & 6.0mm and within treatment range of Chocolate
Touch to be used 1.1:1 at Target Lesion

9. Target Lesion <18cm that consists of no more than two adjacent lesions (<25mm apart)
and is able to be completely covered with inflation of no more than two assigned
balloons

10. Angiographic evidence of distal run-off demonstrated by at least one patent tibial
vessel without evidence of significant (>70%) stenosis from origin to to ankle

11. In-flow vessel without significant stenosis (<70%) or successful treatment (<30%
residual stenosis with no complications) of a diseased iliac vessel

Exclusion Criteria:

1. Acute limb ischemia, or patient indicated for thrombolytic therapy

2. Planned surgery within 30 days including interventions on the non-target limb

3. Target Limb concurrent interventions involving a re-entry device, atherectomy, laser,
or ablation procedures, the use of a drug eluting stent, or, treatment with any other
drug coated balloon

4. Myocardial infarction or stroke within 30 days prior to the procedure

5. Known intolerance to required medications, contrast media, nitinol, or Paclitaxel

6. Known impaired Renal Function that could have an impact on contrast tolerance with
Glomerular filtration rate (GFR) ≤ 30 ml/min per 1.73 m^2 and/or elevated serum
creatinine >2.5mg/dL (220µmol/L)

7. Known bleeding disorder or uncontrolled hypercoagulable disorder

8. Non-atherosclerotic lesion (e.g. vasculitis or Berger's disease)

9. Female who is pregnant or intends to be pregnant during study

10. Patient is enrolled in another clinical study or was previously enrolled in this study

11. Presence of perforation, dissection or other injury at access site or in target vessel
at time of enrollment

12. Severe Calcification at the target lesion (defined as angiographic evidence of dense
calcification present on both sides of the vessel wall on two orthogonal views and
that extends >5 continuous cm in length)

13. Previous bypass graft or stent at target vessel, OR, iliac stent that cannot permit
crossing by the treatment balloon within the introducer sheath
We found this trial at
21
sites
5300 Tallman Ave NW
Seattle, Washington 98122
(206) 782-2700
Principal Investigator: Paul Huang, MD
Swedish Medical Center Since 1910, Swedish has been the region's hallmark for excellence in health...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
201 Dowman Dr
Atlanta, Georgia 30303
(404) 727-6123
Principal Investigator: Krushow Niazi, MD
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Browns Mills, New Jersey 08015
Principal Investigator: Richard Kovach, MD
Phone: 609-893-6611
?
mi
from
Browns Mills, NJ
Click here to add this to my saved trials
Camp Hill, Pennsylvania 17011
Principal Investigator: Rajesh Dave, MD
Phone: 717-724-6304
?
mi
from
Camp Hill, PA
Click here to add this to my saved trials
11100 Euclid Avenue
Cleveland, Ohio 44106
Principal Investigator: Vikram Kashyap, MD
Phone: 216-844-3545
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Dearborn, Michigan 48126
Principal Investigator: Elias Kassab, MD
?
mi
from
Dearborn, MI
Click here to add this to my saved trials
800 Biesterfield Road
Elk Grove Village, Illinois 60007
Principal Investigator: Richard Chamberlain, MD
Phone: 847-427-7230
?
mi
from
Elk Grove Village, IL
Click here to add this to my saved trials
Gainesville, Florida 32605
Principal Investigator: Arthur Lee, MD
Phone: 352-665-2181
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
Graz, 8036
Principal Investigator: Marianne Brodmann, Prof.
?
mi
from
Graz,
Click here to add this to my saved trials
Harrisburg, Pennsylvania 17110
Principal Investigator: Cleon Randolph Hubbard, MD
Phone: 717-920-4400
?
mi
from
Harrisburg, PA
Click here to add this to my saved trials
Houma, Louisiana 70360
Principal Investigator: Craig Walker, MD
?
mi
from
Houma, LA
Click here to add this to my saved trials
Jackson, Mississippi 39216
Principal Investigator: William Crowder, MD
Phone: 601-982-7850
?
mi
from
Jackson, MS
Click here to add this to my saved trials
Kansas City, Missouri 64111
Principal Investigator: Matthew Bunte, MD
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
Kingsport, Tennessee 37660
Principal Investigator: Christopher Metzger, MD
?
mi
from
Kingsport, TN
Click here to add this to my saved trials
Miami Beach, Florida 33140
Principal Investigator: Robert Beasley, MD
?
mi
from
Miami Beach, FL
Click here to add this to my saved trials
New Braunfels, Texas 78130
Principal Investigator: Jayson Yoho, MD
?
mi
from
New Braunfels, TX
Click here to add this to my saved trials
New Braunfels, Texas 78130
Principal Investigator: Jamison Wyatt, MD
?
mi
from
New Braunfels, TX
Click here to add this to my saved trials
1190 5th Avenue
New York, New York 10029
Principal Investigator: Prakash Krishnan, MD
Phone: 646-399-1639
?
mi
from
New York, NY
Click here to add this to my saved trials
New York, New York 10032
Principal Investigator: Sahil Parikh, MD
Phone: 212-342-3485
?
mi
from
New York, NY
Click here to add this to my saved trials
5225 Hampton Place
Saginaw, Michigan 48604
Principal Investigator: John McClure, MD
?
mi
from
Saginaw, MI
Click here to add this to my saved trials
Wynnewood, Pennsylvania 19096
Principal Investigator: Amid Khanh, MD
?
mi
from
Wynnewood, PA
Click here to add this to my saved trials